PGGM Investments Has $14.15 Million Position in Cencora, Inc. (NYSE:COR)

PGGM Investments lessened its stake in Cencora, Inc. (NYSE:COR) by 23.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 62,993 shares of the company’s stock after selling 19,167 shares during the quarter. PGGM Investments’ holdings in Cencora were worth $14,153,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in COR. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Cencora by 122.6% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 342,582 shares of the company’s stock valued at $76,982,000 after acquiring an additional 188,660 shares in the last quarter. Achmea Investment Management B.V. boosted its position in Cencora by 8.5% during the fourth quarter. Achmea Investment Management B.V. now owns 125,870 shares of the company’s stock valued at $28,281,000 after purchasing an additional 9,857 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Cencora by 236.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 10,043 shares of the company’s stock valued at $2,256,000 after purchasing an additional 7,059 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in Cencora by 2.1% in the fourth quarter. Avantax Advisory Services Inc. now owns 17,182 shares of the company’s stock valued at $3,860,000 after purchasing an additional 351 shares in the last quarter. Finally, Great Lakes Advisors LLC increased its position in Cencora by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 384,688 shares of the company’s stock worth $86,432,000 after purchasing an additional 5,529 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

Shares of COR opened at $253.88 on Thursday. The company has a market capitalization of $49.23 billion, a PE ratio of 36.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $263.70. The company’s fifty day moving average price is $246.39 and its 200 day moving average price is $238.81.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.87%. Cencora’s dividend payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent research reports. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Finally, Wells Fargo & Company increased their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.